Skip to main content
. 2020 Mar 26;158(1):195–205. doi: 10.1016/j.chest.2020.03.032

Table 4.

Treatments and Prognosis of the Patients With COVID-19 or H1N1

Variable Total (N = 148) COVID-19 (n = 73) H1N1 (n = 75) P Value
Oxygenation stratification < .001
 Pao2/Fio2 > 200 mm Hg 41 (27.7) 32 (43.8) 9 (12.0)
 100 mm Hg < Pao2/Fio2 ≤ 200 mm Hg 66 (44.6) 36 (49.3) 30 (40.0)
 Pao2/Fio2 ≤ 100 mm Hg 41 (27.7) 5 (6.8) 36 (48.0)
Initial respiratory support < .001
 COT 54 (38.3) 49 (67.1) 5 (7.4)
 HFNC 16 (11.3) 14 (19.2) 2 (2.9)
 NIV 29 (20.6) 5 (6.8) 24 (35.3)
 IMV 42 (29.8) 5 (6.8) 37 (54.4)
 Initial respiratory support failure
 COT failure 20/54 (37.0) 20/49 (40.8) 0/5 (0.0) .145
 HFNC failure 3/16 (18.8) 3/14 (21.4) 0/2 (0.0) .650
 NIV failure 11/29 (37.9) 5/5 (100.0) 6/24 (25.0) .004
Respiratory support during hospitalization
 COT 61 (47.3) 29 (39.7) 32 (57.1) .053
 HFNC 54 (40.6) 22 (30.1) 32 (53.3) .008
 NIV 42 (31.3) 8 (11.0) 34 (55.7) < .001
 IMV 73 (51.4) 14 (19.2) 59 (85.5) < .001
 ECMO 35 (25.2) 10 (13.7) 25 (25.2) .002
Antiviral therapy
 Interferon-α2b 42 (29.8) 42 (62.7)
 Ganciclovir 24 (16.2) 24 (32.9)
 Lopinavir/ritonavir 61 (47.3) 61 (83.6)
 Oseltamivir 102 (68.9) 34 (46.6) 68 (90.7) < .001
Chinese traditional medicine 20 (13.5) 20 (27.4)
Glucocorticoid 94 (64.4) 58 (79.5) 36 (49.3) < .001
 Initial dosage, mg/d 80 (40, 80) 80 (40, 80) 80 (40, 80) .770
 Duration, d 8 (5, 11) 8 (5, 11) 6 (5, 13) .502
Immunoglobulin 65 (43.9) 43 (58.9) 22 (29.3) < .001
Outcome
 Discharge 75 (50.7) 26 (35.6) 49 (65.3) .001
 Death 47 (31.8) 21 (28.8) 26 (34.7) .483
 In-hospital 26 (17.6) 26 (35.6)
 Hospital stay, d 14 (9, 21) 13 (10, 18) 16 (9, 30) .247

Data are presented as medians (interquartile ranges) or No. (%). COT = conventional oxygen therapy; ECMO = extracorporeal membrane oxygenation; HFNC = high-flow nasal cannula oxygen therapy; IMV = invasive mechanical ventilation; NIV = noninvasive mechanical ventilation. See Table 1 legend for expansion of other abbreviations.